S&P Futures
3,964.50 +24.00 (+0.61%) Dow Futures
32,015.00 +135.00 (+0.42%) Nasdaq Futures
11,872.50 +101.50 (+0.86%) Russell 2000 Futures
1,776.70 +12.30 (+0.70%) Crude Oil
111.04 +1.27 (+1.16%) Gold
1,860.30 -5.10 (-0.27%)
Teva Pharmaceutical Industries Limited (TEVA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.45 |
| Open | 8.43 |
| Bid | 8.48 x 4000 |
| Ask | 8.50 x 1100 |
| Day's Range | 8.26 - 8.50 |
| 52 Week Range | 7.23 - 11.55 |
| Volume | |
| Avg. Volume | 9,047,208 |
| Market Cap | 9.4B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.56 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Nov 27, 2017 |
| 1y Target Est | 10.17 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for TEVA
Related Research
- Teva Pharmaceutical IndustriesAnalyst Report: Teva Pharmaceutical Industries LimitedBased in Israel, Teva is one of the world’s largest generic drug manufacturers, with over 3,500 products marketed in over 60 countries. While a majority of its revenue is attributed to prescription generic drugs, Teva develops and markets its own branded specialty and biopharmaceutical products, primarily in the U.S. and in Europe. The company’s branded portfolio generates one fifth of total revenue and consists of patented therapies targeting central nervous system conditions (Austedo, Ajovy, Copaxone), oncology (Bendeka/Treanda), and respiratory conditions (ProAir, Qvar). While global competition has facilitated the commodification of small-molecule generic drugs, Teva’s portfolio rationalization has resulted in less overall price erosion versus peers.RatingFair ValueEconomic Moat21 days agoMorningstar
- Business Wire
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
TEL AVIV, Israel & PARSIPPANY, N.J., May 23, 2022--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new efficacy and safety data from a 3-year open-label extension (OLE) study on AUSTEDO® (deutetrabenazine) tablets in postmenopausal women with tardive dyskinesia (TD). These data will be presented at the 2022 American Psychiatric Association (APA) Annual Meeting, held May 21-25 in New Orleans and online June 7-10. In addition, ne
- Benzinga
Teva Pharmaceutical Shares Real-World Data Of ProAir Digihaler In Asthma Patients
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) announced new study findings based on newly established clinical thresholds on short-acting beta-agonist (SABA) use and real-world usage of ProAir Digihaler (albuterol sulfate) inhalation powder. ProAir Digihaler is a breath-actuated, digital SABA inhaler with built-in flow sensors that detect, record, and store objective data. 89% (319/359) of patients met the consensus threshold of SABA reliever medication use, and 72% (260/359) met the threshold
- Business Wire
United Kingdom first to grant licence for Teva’s ophthalmology biosimilar Ongavia (ranibizumab)▼
AMSTERDAM, May 17, 2022--Teva Pharmaceutical Industries Ltd welcomes the UK Medicines & Healthcare Regulatory Agency (MHRA) decision to grant a licence for Ongavia®, a biosimilar to Lucentis® (ranibizumab ), an eye injection. The United Kingdom is the first country in Europe to authorize commercialization of Ongavia® for the treatment of neovascular (wet) age-related macular degeneration ("AMD"). Ongavia® is also licenced for: the treatment of visual impairment due to diabetic macular oedema (DM
